Massive Bio is listed in the New York Digital Health 100

NEW YORK–(BUSINESS WIRE)–Massive Bio, a leader in using artificial intelligence (AI) to connect cancer patients to clinical trials, is honored to announce that it has been named to the New York Digital Health 100 (DH100) for the second year in a row. The DH100, published annually by Digital Health New York (DHNY), features the New York region’s most exciting and innovative healthcare startups and is included in the 2023 New York Healthcare Innovation Report. Published for the sixth time this year , the report is an in-depth look at the leaders, trends and data shaping health care innovation in New York. DHNY’s stated goal is “to create a connected community that shares ideas, leads in new directions, and builds success for the entire healthcare ecosystem.”

Competition for inclusion in this year’s DH100 was intense, as DHNY received twice as many applications as in 2022. Massive Bio made the list for the second year in a row, being named one of the top 10 companies in Data & Platform: Analytics & Insights category.

“Massive Bio has been headquartered in New York since its founding in 2015, so the choice is very important to us,” said Celine Kurnaz, Co-Founder and CEO of Massive Bio. “Although the healthcare ecosystem includes many complex and challenging processes worldwide, our adventure that started in New York has spread to 12 countries in a short time and reached more than 100,000 cancer patients.”

Massive Bio helps cancer patients around the world access clinical trials of innovative oncology treatments that can help achieve better outcomes. The company’s AI-based technology uses over 170 proprietary algorithms to connect patients worldwide to clinical trials with unparalleled precision. Using NLP, Computer Vision and other forms of AI, Massive Bio’s extracts data from patients’ medical records, then identifies clinical trial matches through a process overseen by a certified oncology case manager.

“Our platform is a tool for finding clinical trials, a source of hope and a signal of progress in the fight against cancer,” says Kurnaz. “We believe that artificial intelligence can transform healthcare and improve outcomes for cancer patients, and our inclusion in the New York Digital Health 100 is a testament to that.” Our AI-based platform represents the intersection of technology and humanity as we strive to empower cancer patients to take control of their health journey through real-time access to clinical trial information.”

Massive Bio will continue to innovate and develop its AI capabilities, added Arturo Loaiza-Bonilla, MD, Co-Founder and Chief Medical Officer of Massive Bio. “As we build these capabilities, every cancer patient can do what’s possible by leveraging technology and providing real-time information and insights.” We are committed to creating a future where there is access to the best care,” says Loaiza-Bonilla. “We envision a world where patients are no longer burdened with navigating clinical research and can focus on what matters, like their health and well-being. At the core of our mission is the belief that every cancer patient deserves the opportunity to explore all possible treatment options, and our platform is committed to making that a reality.”

About Massive Bio

Massive Bio empowers cancer patients to find the best treatment options and provides convenient access and enrollment services to global oncology clinical trials powered by advanced artificial intelligence. Founded on the belief that all people should have equal access to cutting-edge treatments, Massive Bio combines a best-in-class artificial intelligence platform with concierge-level services, removing many of the barriers cancer patients face when enrolling and participation in clinical trials. Headquartered in New York and featuring more than 100,000 patients on its platform, Massive Bio operates in 12 countries.

You can reach Massive Bio via [email protected], Twitter, LinkedInand Facebook.

Leave a Comment

Your email address will not be published. Required fields are marked *